Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by AstraZeneca
Sponsor:
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00658021
First received: April 8, 2008
Last updated: February 9, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2020
  Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)